89892-21-7

Basic information

• Product Name: 6-Bromoquinazoline
• Synonyms: 6-BROMO-QUINAZOLINE;4-chloro-8-methoxyquinazoline;Quinazoline, 6-bromo-;6-Bromoquizoline
• CAS NO: 89892-21-7
• Molecular Formula: C₈H₅BrN₂
• Molecular Weight: 209.04
• Product Categories: CHIRAL CHEMICALS
• Mol File: 89892-21-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 136-138 °C
• Boiling Point: 304.254 °C at 760 mmHg
• Flash Point: 137.808 °C
• Appearance: /
• Density: 1.657 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.685
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.61±0.26(Predicted)
• CAS DataBase Reference: 6-Bromoquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoquinazoline(89892-21-7)
• EPA Substance Registry System: 6-Bromoquinazoline(89892-21-7)

Safety Data

• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 89892-21-7(Hazardous Substances Data)

Usage

Uses

6-Bromoquinazoline is a reagent for structure-based design of biaryl mannoside fimH inhibitors for use in urinary infection treatment.

InChI:InChI=1/C8H5BrN2/c9-7-1-2-8-6(3-7)4-10-5-11-8/h1-5H

Upstream product

• 253-82-7 quinazoline 

Downstream Products

• 1093818-79-1 N-(2-chloro-5-(quinazolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1312448-28-4 N-(2-chloro-5-(quinazolin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1373346-94-1 4-(quinazolin-6-yl)phenyl α-D-mannopyranoside 
• 1416455-36-1 6-(2-fluoro-4-methyl-5-((2,2,2-trifluoroethyl)thio)phenyl)quinazoline 
• 1375301-92-0 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazoline 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 

Relevant articles and documents

USE OF TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to methods of using the compounds of the invention, including trifluoromethyl substituted benzamide compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.